Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BCDA 
Biocardia Inc (BCDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: BCDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.69% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.55M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 1 | Beta 0.79 | 52 Weeks Range 1.00 - 3.20 | Updated Date 10/16/2025 |
52 Weeks Range 1.00 - 3.20 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -222.28% | Return on Equity (TTM) -737.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14086790 | Price to Sales(TTM) 3089.53 |
Enterprise Value 14086790 | Price to Sales(TTM) 3089.53 | ||
Enterprise Value to Revenue 3111.7 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 10608734 | Shares Floating 4156867 |
Shares Outstanding 10608734 | Shares Floating 4156867 | ||
Percent Insiders 18.37 | Percent Institutions 2.87 |
Upturn AI SWOT
Biocardia Inc
Company Overview
History and Background
BioCardia, Inc. was founded in 1998. It's a clinical-stage biotherapeutic company focused on developing cellular and cell-derived therapies for cardiovascular diseases.
Core Business Areas
- CardiAMP Cell Therapy System: The CardiAMP Cell Therapy System is BioCardia's lead product candidate, designed to use a patient's own bone marrow cells to treat heart failure.
- AVANCE Clinical Trial: The AVANCE clinical trial, part of the CardiAMP program, is evaluating the efficacy of the cell therapy system in patients with chronic heart failure.
Leadership and Structure
The company is led by its CEO, Peter Altman. The organizational structure includes departments focused on research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- CardiAMP Cell Therapy System: This is BioCardia's primary product candidate. It uses a patient's own bone marrow cells to repair damaged heart tissue. It is still in clinical trials so no revenue is generated, nor any market share. Competitors include companies developing cell therapies for cardiovascular disease, such as Mesoblast and Capricor Therapeutics, and those developing other heart failure treatments like Novartis with Entresto.
Market Dynamics
Industry Overview
The cell therapy market for cardiovascular disease is growing, driven by the increasing prevalence of heart failure and the need for new treatment options. Regulatory pathways for cell therapies are becoming more defined.
Positioning
BioCardia is a clinical-stage company aiming to establish itself as a leader in cell-based therapies for heart failure. Their competitive advantage lies in their proprietary CardiAMP technology and their personalized approach to cell therapy. Their total addressable market depends on approval from the FDA
Total Addressable Market (TAM)
The TAM for heart failure therapies is substantial, estimated in the billions of dollars annually. BioCardia's potential market share depends on successful clinical trial outcomes and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary CardiAMP technology
- Personalized approach to cell therapy
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Small market capitalization
Opportunities
- Successful completion of clinical trials
- FDA approval of CardiAMP Cell Therapy System
- Partnerships with larger pharmaceutical companies
- Expansion into new cardiovascular indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapy companies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MESO
- CAPR
Competitive Landscape
BioCardia faces competition from other cell therapy companies and established pharmaceutical companies with heart failure therapies. BioCardia's strengths lie in its CardiAMP technology and personalized approach, while its weaknesses include being a clinical-stage company with no approved products. The total available market for Heart failure therapy is $3.74 Billion in 2024.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal, as the company is primarily focused on research and development.
Future Projections: Future growth is dependent on clinical trial success and regulatory approval. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include advancing the CardiAMP cell therapy system through clinical trials and pursuing partnerships with other healthcare companies.
Summary
BioCardia is a clinical-stage biopharmaceutical company focused on cell therapy for cardiovascular disease. Their future depends on successful clinical trial outcomes and regulatory approval for its CardiAMP therapy. The company has proprietary technology, but also significant financial risks. They need to focus on moving from the clinic to commercialisation and ensure cash flow is available for the next few years.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated. Market share estimates are approximate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biocardia Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2008-03-14 | CEO, President & Director Dr. Peter A. Altman Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.biocardia.com |
Full time employees 17 | Website https://www.biocardia.com | ||
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.